Ruthra Medicines

Ruthra Medicines is a biotechnology company dedicated to developing first-in-class small molecule therapeutics that modulate the Integrated Stress Response (ISR). The company's lead program targets the eukaryotic translation initiation factor 2B (eIF2B) complex, which plays a critical role in regulating protein synthesis under cellular stress. Ruthra's primary focus is on Vanishing White Matter Disease (VWMD), a devastating genetic leukodystrophy with no current cure. Beyond rare neurological disorders, the company explores the application of ISR modulation in oncology and other neurodegenerative conditions. Based in the San Francisco Bay Area, Ruthra is backed by prominent life science investors and led by a team with deep expertise in stress biology and drug discovery.